丽珠( Livzon) www.livzon.comwww.livzon.com.cn 
丽珠集团创建于1985年1月,当时利用特区的地缘和政策优势，积极开展进出口贸易，不断发展壮大；在“科技兴企”方针指导下，集团开发出以“丽珠得乐”为代表的一系列拳头产品，以产品的高科技含量和有效的推广和销售方式，迅速占领市场，取得良好的经济效益，使丽珠进入高速发展的轨道。

1993年丽珠成为国内首家股A、B上市的公众公司。

自2002年起公司进入了第二次创业阶段。集团在以企业家朱保国为首的董事会的领导下，规划了五年内的发展前景，全面实施规范化的流程管理，精益生产，质量第一，产品成为医患人员信得过的知名大品牌，实现了企业的健康发展。

经过22年努力，丽珠集团已经成为集医药产品科研、开发、生产、销售于一体的综合性、高新技术型制药企业集团，在处方药的生产与销售领域具有突出优势，丽珠集团目前在产品种300余个，类别涉及化学药品、生化药品、生物工程药品、微生态制剂、中成药、诊断试剂等，产品领域涉及消化道、心脑血管、抗感染、生殖内分泌等领域，药物制剂的主要品牌有丽珠得乐系列、抗病毒颗粒、参芪扶正注射液、脑力隆、丽珠威，以及丽珠肠乐、前列安栓、丽珠赛乐、丽珠广乐、利脉胶囊等重点品种；另外还拥有抗生素、他汀类及氨基糖苷类原料药等大型生产基地。

丽珠集团致力于人类生命常青的事业，未来五年的发展战略目标已经明确：在2010年前进入中国制药工业企业前五名。

Livzon Pharmaceutical Group Inc., founded in the year of 1985, has already established itself as one of the leading pharmaceutical company in China. In 1993, Livzon became the first local pharmaceutical company to list both A and B shares, with multifold turnover in development, manufacture, and marketing of diversified pharmaceutical products. After a consistent growth, it possesses a total capital of £¤2.2 billion RMB inclusive of 24 controlled subsidiaries and joint ventures.
With 9 affiliated plants equipped by advanced facilities, the dynamic production chain efficiently operates to manufacture APIs, finished dosage forms, diagnostic agents and bioactive material, characterized by know-how of fermentation, synthesis, gene recombination, biological extraction, and traditional Chinese medicines, with more than 300 items therapeutically grouped as gastrointestinal, anti-infectious (antibacterial, antiviral), cardiovascular, anti-cancer, immunomodulant, reproductive, neurological, urological, dermatological and pediatric agents. Meanwhile, Livzon possesses 4 Production Bases as leading manufacturer of specialist APIs such as fermented antibiotics, sterile cephalosporins, carbapenems, and hypolipemic "Statins". 
Livzon's strong foundation lies in quality, and there are 38 production lines in compliance with WHO GMP requirements, including some DMFs and EDMFs documentation, as well as USA FDA inspection, COS and COSHER approvals. Benefited from the regulatory compliance, an extensive overseas market is under robust development, with prosperous vision in Canada, Japan, Middle East, South Africa, South East Asia, and West Europe.
Livzon's core competence has been reinforced by its 3 R& D Centers with vigorous activities in developing innovative technology and products. Meanwhile, Livzon has pioneered the international Licensee-Agreement for developing and marketing patented medicines in China by simultaneous or even prior timeline with overseas counterparts. Livzon has also maintained a superior position in Chinese medicine market, guaranteed by its competent sales force and large distribution network all over the country. 
Livzon is striving not only to stand among the top pharmaceutical companies in China, but establish itself a reliable partner for a number of world's leading pharmaceutical companies.